(VIANEWS) – Graham Holdings Company (GHC), Hyatt Hotels Corporation (H), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Graham Holdings Company (GHC)
14.3% sales growth and 4.02% return on equity
Graham Holdings Company, through its subsidiaries, operates as a diversified education and media company in the United States and internationally. It provides test preparation services and materials; professional training and exam preparation for professional certifications and licensures; and non-academic operations support services to the Purdue University Global; operations support services for online courses and programs; training and test preparation services for accounting and financial services professionals; English-language training, academic preparation programs, and test preparation for English proficiency exams; and A-level examination preparation services, as well as operates colleges, business school, higher education institution, and an online learning institution. The company also owns and operates television stations, restaurants, and entertainment venues; engages in the financial training and automobile dealerships business; offers social media management tools to connect newsrooms with their users; produces Foreign Policy magazine and ForeignPolicy.com website; and publishes Slate, an online magazine, as well as French-language news magazine websites at slate.fr and slateafrique.com. In addition, it provides social media marketing solutions; home health, hospice, and palliative services; burners, igniters, dampers, and controls; screw jacks, linear actuators, and related linear motion products, and lifting systems; pressure impregnated kiln-dried lumber and plywood products; digital advertising services; power charging and data systems, industrial and commercial indoor lighting solutions, and electrical components and assemblies; dermatology and professional aesthetics, and skin care services; software and services; and operates pharmacy. The company was formerly known as The Washington Post Company and changed its name to Graham Holdings Company in November 2013. Graham Holdings Company was founded in 1877 and is based in Arlington, Virginia.
Earnings Per Share
As for profitability, Graham Holdings Company has a trailing twelve months EPS of $33.43.
PE Ratio
Graham Holdings Company has a trailing twelve months price to earnings ratio of 20.4. Meaning, the purchaser of the share is investing $20.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.02%.
Volume
Today’s last reported volume for Graham Holdings Company is 3672 which is 75.39% below its average volume of 14926.
2. Hyatt Hotels Corporation (H)
11.1% sales growth and 13.87% return on equity
Hyatt Hotels Corporation operates as a hospitality company in the United States and internationally. It operates through Owned and Leased Hotels, Americas Management and Franchising, ASPAC Management and Franchising, EAME/SW Asia Management and Franchising, and Apple Leisure Group segments. The company manages, franchises, licenses, owns, and leases portfolio of properties, consisting of full-service hotels, select service hotels, resorts, and other properties, including timeshare, fractional, residential, vacation, and condominium units. It operates its properties under the Park Hyatt, Miraval, Grand Hyatt, Alila, Andaz, The Unbound Collection by Hyatt, Destination, Hyatt Regency, Hyatt, Thompson Hotels, Hyatt Centric, Joie de Vivre, Caption by Hyatt, Hyatt House, Hyatt Place, Hyatt Ziva, Hyatt Zilara, UrCove, Hyatt Residence Club, Hyatt Residences, Hyatt Resorts, Secrets Resorts & Spas, Dreams Resorts & Spas, Breathless Resorts & Spas, Zoetry Wellness & Spa Resorts, Alua Hotels & Resorts, and Sunscape Resorts & Spas brands. As of September 30, 2022, the company's hotel portfolio consisted of approximately 1,200 hotels in 72 countries across six continents. It primarily serves corporations; national, state, and regional associations; specialty market accounts, including social, government, military, educational, religious, and fraternal organizations; travel agency and luxury organizations; and a group of individual consumers. The company also operates World of Hyatt loyalty program which rewards points that can be redeemed for hotel nights and other rewards. Hyatt Hotels Corporation was founded in 1957 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Hyatt Hotels Corporation has a trailing twelve months EPS of $4.45.
PE Ratio
Hyatt Hotels Corporation has a trailing twelve months price to earnings ratio of 26.54. Meaning, the purchaser of the share is investing $26.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.87%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.8%, now sitting on 3.59B for the twelve trailing months.
Moving Average
Hyatt Hotels Corporation’s worth is way above its 50-day moving average of $107.14 and above its 200-day moving average of $111.99.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Hyatt Hotels Corporation’s EBITDA is 2.25.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 20, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 0.51%.
3. Vertex Pharmaceuticals (VRTX)
7.5% sales growth and 23.49% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.3.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 30.47. Meaning, the purchaser of the share is investing $30.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.49%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 8.2% and 33.4%, respectively.
Volume
Today’s last reported volume for Vertex Pharmaceuticals is 255928 which is 82.01% below its average volume of 1422710.
Previous days news about Vertex Pharmaceuticals(VRTX)
- According to Zacks on Tuesday, 19 December, "Charles River Laboratories International, Inc. (CRL Quick QuoteCRL – Free Report) recently achieved an important milestone in its strategic collaboration with Vertex Pharmaceuticals to manufacture CASGEVY (exagamglogene autotemcel [exa-cel]). "
- According to Zacks on Monday, 18 December, "Vertex Pharmaceuticals Incorporated price-consensus-chart | Vertex Pharmaceuticals Incorporated Quote"
- According to Zacks on Monday, 18 December, "The company has partnered with Vertex Pharmaceuticals for the development and commercialization of Casgevy. "
- The zacks analyst blog highlights novo nordisk, eli lilly, vertex pharmaceuticals, regeneron and GSK. According to Zacks on Tuesday, 19 December, "Stocks recently featured in the blog include: Novo Nordisk (NVO Quick QuoteNVO – Free Report) , Eli Lilly (LLY Quick QuoteLLY – Free Report) , Vertex Pharmaceuticals Inc. (VRTX Quick QuoteVRTX – Free Report) , Regeneron (REGN Quick QuoteREGN – Free Report) and GSK plc (GSK Quick QuoteGSK – Free Report) .", "Nonetheless, a few big drugmakers, Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals Inc., Regeneron and GSK plc, have outperformed the industry this year. "
4. Calix (CALX)
7% sales growth and 6.84% return on equity
Calix, Inc., together with its subsidiaries, provides cloud and software platforms, and systems and services in the United States, the Middle East, Canada, Europe, the Caribbean, and internationally. The company's cloud and software platforms, and systems and services enable communication service providers (CSPs) to provide a range of services. It provides Calix Cloud platform, a role-based analytics platform comprising Calix Marketing Cloud, Calix Support Cloud, and Calix Operations Cloud, which are configurable to display role-based insights and enable CSPs to anticipate and target new revenue-generating services and applications through mobile application. The company also offers EXOS, a carrier class smart home and business operating system that supports residential, business, and mobile subscribers; and AXOS, an operating system for access networks that allows a service provider to deliver all services on a single, elastic, converged access network that is always on, simple to operate, and quick to deploy. It offers its products through its direct sales force and resellers. Calix, Inc. was incorporated in 1999 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, Calix has a trailing twelve months EPS of $0.7.
PE Ratio
Calix has a trailing twelve months price to earnings ratio of 61.06. Meaning, the purchaser of the share is investing $61.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.84%.
Moving Average
Calix’s worth is above its 50-day moving average of $39.10 and under its 200-day moving average of $45.21.
